Review



t5 2 caption a7 species strain mic  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC t5 2 caption a7 species strain mic
    T5 2 Caption A7 Species Strain Mic, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 2852 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/t5 2 caption a7 species strain mic/product/ATCC
    Average 99 stars, based on 2852 article reviews
    t5 2 caption a7 species strain mic - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    t5 2 caption a7 species strain mic  (ATCC)
    99
    ATCC t5 2 caption a7 species strain mic
    T5 2 Caption A7 Species Strain Mic, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/t5 2 caption a7 species strain mic/product/ATCC
    Average 99 stars, based on 1 article reviews
    t5 2 caption a7 species strain mic - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    caption a7 species strain mic  (ATCC)
    99
    ATCC caption a7 species strain mic
    Caption A7 Species Strain Mic, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/caption a7 species strain mic/product/ATCC
    Average 99 stars, based on 1 article reviews
    caption a7 species strain mic - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    caption a7 species strain identifier genotype modal range tebipenem mic  (ATCC)
    99
    ATCC caption a7 species strain identifier genotype modal range tebipenem mic
    Challenge strains used in this study
    Caption A7 Species Strain Identifier Genotype Modal Range Tebipenem Mic, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/caption a7 species strain identifier genotype modal range tebipenem mic/product/ATCC
    Average 99 stars, based on 1 article reviews
    caption a7 species strain identifier genotype modal range tebipenem mic - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    caption a7 strain species origin mic  (ATCC)
    99
    ATCC caption a7 strain species origin mic
    Challenge strains used in this study
    Caption A7 Strain Species Origin Mic, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/caption a7 strain species origin mic/product/ATCC
    Average 99 stars, based on 1 article reviews
    caption a7 strain species origin mic - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Challenge strains used in this study

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

    doi: 10.1128/AAC.00603-19

    Figure Lengend Snippet: Challenge strains used in this study

    Article Snippet: The genotypes of the challenge strains are shown in . table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Species Strain identifier Genotype Modal (range) tebipenem MIC (mg/liter) E. coli NCTC 13462 CTX-M2 0.016 (0.016) E. coli ATCC 35218 TEM-1 ESBL 0.016 (0.008–0.016) E. coli ATCC 25922 Wild type 0.016 (0.008–0.016) E. coli SPT 719 (JMI 742654) SHV-12, TEM-1 0.03 (0.03–0.25) E. coli SPT 720 (JMI 850505) mcr-1 , CMY-2, OXA-1, TEM1 0.5 (0.25–0.5) E. coli SPT 731 (JMI 845741) CTX-M-15, OXA-1/30, TEM-1 ST131 a O25b clade 0.03 (0.015–0.03) K. pneumoniae NCTC 13465 ESBL and CTX-M25 0.03 (0.015–0.03) K. pneumoniae ATCC 27736 Wild type 0.03 (0.03–0.06) K. pneumoniae SPT 725 (JMI 776273) SHV-12 0.125 (0.06–0.25) K. pneumoniae SPT 722 (JMI 934954) CTX-M-15, OXA-1, OXA-9, SHV-28, TEM-1, OmpK35 disrupted, OmpK36 altered 0.25 (0.12–0.5) K. pneumoniae SPT 723 (JMI 632346) CTX-M-15, OXA-1, SHV-12 0.125 (0.12) Open in a separate window a ST131, sequence type 131.

    Techniques:

    Pharmacodynamics of tebipenem against E. coli ATCC 25922 in a neutropenic thigh infection model. The data are the mean ± standard deviation for 3 mice collected over the course of three independently conducted experiments. The solid squares are the bacterial density at the commencement of therapy, which was at 2 h postinoculation. The mean of these points defines the stasis line, depicted by the broken horizontal line. The open circles are the data points from mice sacrificed after receiving 24 h of antibacterial therapy. The solid line is the fit of an inhibitory sigmoid Emax model.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

    doi: 10.1128/AAC.00603-19

    Figure Lengend Snippet: Pharmacodynamics of tebipenem against E. coli ATCC 25922 in a neutropenic thigh infection model. The data are the mean ± standard deviation for 3 mice collected over the course of three independently conducted experiments. The solid squares are the bacterial density at the commencement of therapy, which was at 2 h postinoculation. The mean of these points defines the stasis line, depicted by the broken horizontal line. The open circles are the data points from mice sacrificed after receiving 24 h of antibacterial therapy. The solid line is the fit of an inhibitory sigmoid Emax model.

    Article Snippet: The genotypes of the challenge strains are shown in . table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Species Strain identifier Genotype Modal (range) tebipenem MIC (mg/liter) E. coli NCTC 13462 CTX-M2 0.016 (0.016) E. coli ATCC 35218 TEM-1 ESBL 0.016 (0.008–0.016) E. coli ATCC 25922 Wild type 0.016 (0.008–0.016) E. coli SPT 719 (JMI 742654) SHV-12, TEM-1 0.03 (0.03–0.25) E. coli SPT 720 (JMI 850505) mcr-1 , CMY-2, OXA-1, TEM1 0.5 (0.25–0.5) E. coli SPT 731 (JMI 845741) CTX-M-15, OXA-1/30, TEM-1 ST131 a O25b clade 0.03 (0.015–0.03) K. pneumoniae NCTC 13465 ESBL and CTX-M25 0.03 (0.015–0.03) K. pneumoniae ATCC 27736 Wild type 0.03 (0.03–0.06) K. pneumoniae SPT 725 (JMI 776273) SHV-12 0.125 (0.06–0.25) K. pneumoniae SPT 722 (JMI 934954) CTX-M-15, OXA-1, OXA-9, SHV-28, TEM-1, OmpK35 disrupted, OmpK36 altered 0.25 (0.12–0.5) K. pneumoniae SPT 723 (JMI 632346) CTX-M-15, OXA-1, SHV-12 0.125 (0.12) Open in a separate window a ST131, sequence type 131.

    Techniques: Infection, Standard Deviation

    Pharmacokinetics of tebipenem. The data are the mean ± standard deviation for 3 mice. A destructive design was used. Mice sampled in the period from 16 to 24 h had received drug at 0, 8, and 16 h. The mice were infected with E. coli ATCC 25922.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

    doi: 10.1128/AAC.00603-19

    Figure Lengend Snippet: Pharmacokinetics of tebipenem. The data are the mean ± standard deviation for 3 mice. A destructive design was used. Mice sampled in the period from 16 to 24 h had received drug at 0, 8, and 16 h. The mice were infected with E. coli ATCC 25922.

    Article Snippet: The genotypes of the challenge strains are shown in . table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Species Strain identifier Genotype Modal (range) tebipenem MIC (mg/liter) E. coli NCTC 13462 CTX-M2 0.016 (0.016) E. coli ATCC 35218 TEM-1 ESBL 0.016 (0.008–0.016) E. coli ATCC 25922 Wild type 0.016 (0.008–0.016) E. coli SPT 719 (JMI 742654) SHV-12, TEM-1 0.03 (0.03–0.25) E. coli SPT 720 (JMI 850505) mcr-1 , CMY-2, OXA-1, TEM1 0.5 (0.25–0.5) E. coli SPT 731 (JMI 845741) CTX-M-15, OXA-1/30, TEM-1 ST131 a O25b clade 0.03 (0.015–0.03) K. pneumoniae NCTC 13465 ESBL and CTX-M25 0.03 (0.015–0.03) K. pneumoniae ATCC 27736 Wild type 0.03 (0.03–0.06) K. pneumoniae SPT 725 (JMI 776273) SHV-12 0.125 (0.06–0.25) K. pneumoniae SPT 722 (JMI 934954) CTX-M-15, OXA-1, OXA-9, SHV-28, TEM-1, OmpK35 disrupted, OmpK36 altered 0.25 (0.12–0.5) K. pneumoniae SPT 723 (JMI 632346) CTX-M-15, OXA-1, SHV-12 0.125 (0.12) Open in a separate window a ST131, sequence type 131.

    Techniques: Standard Deviation, Infection

    Pharmacodynamics of tebipenem following a single dose of prodrug, administered at 2 h postinoculation. Data are mean ± standard deviation for 3 mice. The solid lines are the fits of the PK-PD mathematical model to each cohort of mice (i.e., the Bayesian posterior estimates were used, with an individual being represented by the cohort of mice). The large arrows show the time of drug administration, and the small arrows show the predicted time that free plasma drug concentrations fell beneath the MIC of 0.015 mg/liter. The data point at the time of treatment initiation is common to each of the cohorts. (A) Controls; (B) 6.67 mg/kg once; (C) 16.67 mg/kg once; (D) 33.33 mg/kg once. There was a negligible persistent effect since bacterial growth commenced immediately after the free plasma drug concentrations fell beneath the MIC.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

    doi: 10.1128/AAC.00603-19

    Figure Lengend Snippet: Pharmacodynamics of tebipenem following a single dose of prodrug, administered at 2 h postinoculation. Data are mean ± standard deviation for 3 mice. The solid lines are the fits of the PK-PD mathematical model to each cohort of mice (i.e., the Bayesian posterior estimates were used, with an individual being represented by the cohort of mice). The large arrows show the time of drug administration, and the small arrows show the predicted time that free plasma drug concentrations fell beneath the MIC of 0.015 mg/liter. The data point at the time of treatment initiation is common to each of the cohorts. (A) Controls; (B) 6.67 mg/kg once; (C) 16.67 mg/kg once; (D) 33.33 mg/kg once. There was a negligible persistent effect since bacterial growth commenced immediately after the free plasma drug concentrations fell beneath the MIC.

    Article Snippet: The genotypes of the challenge strains are shown in . table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Species Strain identifier Genotype Modal (range) tebipenem MIC (mg/liter) E. coli NCTC 13462 CTX-M2 0.016 (0.016) E. coli ATCC 35218 TEM-1 ESBL 0.016 (0.008–0.016) E. coli ATCC 25922 Wild type 0.016 (0.008–0.016) E. coli SPT 719 (JMI 742654) SHV-12, TEM-1 0.03 (0.03–0.25) E. coli SPT 720 (JMI 850505) mcr-1 , CMY-2, OXA-1, TEM1 0.5 (0.25–0.5) E. coli SPT 731 (JMI 845741) CTX-M-15, OXA-1/30, TEM-1 ST131 a O25b clade 0.03 (0.015–0.03) K. pneumoniae NCTC 13465 ESBL and CTX-M25 0.03 (0.015–0.03) K. pneumoniae ATCC 27736 Wild type 0.03 (0.03–0.06) K. pneumoniae SPT 725 (JMI 776273) SHV-12 0.125 (0.06–0.25) K. pneumoniae SPT 722 (JMI 934954) CTX-M-15, OXA-1, OXA-9, SHV-28, TEM-1, OmpK35 disrupted, OmpK36 altered 0.25 (0.12–0.5) K. pneumoniae SPT 723 (JMI 632346) CTX-M-15, OXA-1, SHV-12 0.125 (0.12) Open in a separate window a ST131, sequence type 131.

    Techniques: Standard Deviation

    Dose fractionation study. Regression of the various pharmacodynamic indices versus the observed antibacterial effect when various total daily dosages were administered q8h, q12h, and q24h. Each data point is the mean ± standard deviation for 4 mice. There was not a strong relationship between fCmax/MIC and effect (panel A). Tebipenem appeared to display time-dependent pharmacodynamics, but the fT>MIC plot (B) showed clumping of the data at 100% fT>MIC. There was a relationship between fAUC/MIC and effect, although there were some outlying points (panel C). The relationships with fCmin/MIC versus effect (D) and fAUC0-24/MIC · 1/tau (E) are two alternative time-dependent indices.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

    doi: 10.1128/AAC.00603-19

    Figure Lengend Snippet: Dose fractionation study. Regression of the various pharmacodynamic indices versus the observed antibacterial effect when various total daily dosages were administered q8h, q12h, and q24h. Each data point is the mean ± standard deviation for 4 mice. There was not a strong relationship between fCmax/MIC and effect (panel A). Tebipenem appeared to display time-dependent pharmacodynamics, but the fT>MIC plot (B) showed clumping of the data at 100% fT>MIC. There was a relationship between fAUC/MIC and effect, although there were some outlying points (panel C). The relationships with fCmin/MIC versus effect (D) and fAUC0-24/MIC · 1/tau (E) are two alternative time-dependent indices.

    Article Snippet: The genotypes of the challenge strains are shown in . table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Species Strain identifier Genotype Modal (range) tebipenem MIC (mg/liter) E. coli NCTC 13462 CTX-M2 0.016 (0.016) E. coli ATCC 35218 TEM-1 ESBL 0.016 (0.008–0.016) E. coli ATCC 25922 Wild type 0.016 (0.008–0.016) E. coli SPT 719 (JMI 742654) SHV-12, TEM-1 0.03 (0.03–0.25) E. coli SPT 720 (JMI 850505) mcr-1 , CMY-2, OXA-1, TEM1 0.5 (0.25–0.5) E. coli SPT 731 (JMI 845741) CTX-M-15, OXA-1/30, TEM-1 ST131 a O25b clade 0.03 (0.015–0.03) K. pneumoniae NCTC 13465 ESBL and CTX-M25 0.03 (0.015–0.03) K. pneumoniae ATCC 27736 Wild type 0.03 (0.03–0.06) K. pneumoniae SPT 725 (JMI 776273) SHV-12 0.125 (0.06–0.25) K. pneumoniae SPT 722 (JMI 934954) CTX-M-15, OXA-1, OXA-9, SHV-28, TEM-1, OmpK35 disrupted, OmpK36 altered 0.25 (0.12–0.5) K. pneumoniae SPT 723 (JMI 632346) CTX-M-15, OXA-1, SHV-12 0.125 (0.12) Open in a separate window a ST131, sequence type 131.

    Techniques: Fractionation, Standard Deviation

    Pharmacodynamics of tebipenem against E. coli and K. pneumoniae. Data are the mean ± standard deviation for 3 mice. (A) Pharmacodynamics of E. coli versus K. pneumoniae; (B) pharmacodynamics of ESBL-producing Enterobacteriaceae versus the wild type. Data from the strains were comodeled using fAUC0-24/MIC · 1/tau.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

    doi: 10.1128/AAC.00603-19

    Figure Lengend Snippet: Pharmacodynamics of tebipenem against E. coli and K. pneumoniae. Data are the mean ± standard deviation for 3 mice. (A) Pharmacodynamics of E. coli versus K. pneumoniae; (B) pharmacodynamics of ESBL-producing Enterobacteriaceae versus the wild type. Data from the strains were comodeled using fAUC0-24/MIC · 1/tau.

    Article Snippet: The genotypes of the challenge strains are shown in . table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Species Strain identifier Genotype Modal (range) tebipenem MIC (mg/liter) E. coli NCTC 13462 CTX-M2 0.016 (0.016) E. coli ATCC 35218 TEM-1 ESBL 0.016 (0.008–0.016) E. coli ATCC 25922 Wild type 0.016 (0.008–0.016) E. coli SPT 719 (JMI 742654) SHV-12, TEM-1 0.03 (0.03–0.25) E. coli SPT 720 (JMI 850505) mcr-1 , CMY-2, OXA-1, TEM1 0.5 (0.25–0.5) E. coli SPT 731 (JMI 845741) CTX-M-15, OXA-1/30, TEM-1 ST131 a O25b clade 0.03 (0.015–0.03) K. pneumoniae NCTC 13465 ESBL and CTX-M25 0.03 (0.015–0.03) K. pneumoniae ATCC 27736 Wild type 0.03 (0.03–0.06) K. pneumoniae SPT 725 (JMI 776273) SHV-12 0.125 (0.06–0.25) K. pneumoniae SPT 722 (JMI 934954) CTX-M-15, OXA-1, OXA-9, SHV-28, TEM-1, OmpK35 disrupted, OmpK36 altered 0.25 (0.12–0.5) K. pneumoniae SPT 723 (JMI 632346) CTX-M-15, OXA-1, SHV-12 0.125 (0.12) Open in a separate window a ST131, sequence type 131.

    Techniques: Standard Deviation

    Histogram of the magnitude of the fAUC0-24/MIC · 1/tau value required to achieve stasis for tebipenem against strains of E. coli (n = 6) and K. pneumoniae (n = 5). The median fAUC0-24/MIC · 1/tau value was 23.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

    doi: 10.1128/AAC.00603-19

    Figure Lengend Snippet: Histogram of the magnitude of the fAUC0-24/MIC · 1/tau value required to achieve stasis for tebipenem against strains of E. coli (n = 6) and K. pneumoniae (n = 5). The median fAUC0-24/MIC · 1/tau value was 23.

    Article Snippet: The genotypes of the challenge strains are shown in . table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Species Strain identifier Genotype Modal (range) tebipenem MIC (mg/liter) E. coli NCTC 13462 CTX-M2 0.016 (0.016) E. coli ATCC 35218 TEM-1 ESBL 0.016 (0.008–0.016) E. coli ATCC 25922 Wild type 0.016 (0.008–0.016) E. coli SPT 719 (JMI 742654) SHV-12, TEM-1 0.03 (0.03–0.25) E. coli SPT 720 (JMI 850505) mcr-1 , CMY-2, OXA-1, TEM1 0.5 (0.25–0.5) E. coli SPT 731 (JMI 845741) CTX-M-15, OXA-1/30, TEM-1 ST131 a O25b clade 0.03 (0.015–0.03) K. pneumoniae NCTC 13465 ESBL and CTX-M25 0.03 (0.015–0.03) K. pneumoniae ATCC 27736 Wild type 0.03 (0.03–0.06) K. pneumoniae SPT 725 (JMI 776273) SHV-12 0.125 (0.06–0.25) K. pneumoniae SPT 722 (JMI 934954) CTX-M-15, OXA-1, OXA-9, SHV-28, TEM-1, OmpK35 disrupted, OmpK36 altered 0.25 (0.12–0.5) K. pneumoniae SPT 723 (JMI 632346) CTX-M-15, OXA-1, SHV-12 0.125 (0.12) Open in a separate window a ST131, sequence type 131.

    Techniques:

    Hollow-fiber infection model. The challenge strain (SPT719) used in this experiment is an ESBL-producing E. coli strain (tebipenem MIC, 0.03 mg/liter). Each panel represents the data from an individual fiber. The data represent the total bacterial population (open red triangles), a resistant subpopulation (open blue circles), and the pharmacokinetic profile of tebipenem (open black squares). The outputs from the mathematical model are shown using the same colors. The Bayesian posterior estimates for each fiber are shown. The fAUC0-24/MIC · 1/tau index values associated with the q24h, q12h, q8h, and q6h schedules are 17.3, 34.58, 51.87, and 69.15, respectively. Logarithmic killing was observed with at fAUC0-24/MIC · 1/tau values of 34.58 to 51.87, and suppression of resistance was observed at a value of 69.15. Panel A shows the control. In panels B to E, the same total amount of SPR859 has been administered in different schedules.

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

    doi: 10.1128/AAC.00603-19

    Figure Lengend Snippet: Hollow-fiber infection model. The challenge strain (SPT719) used in this experiment is an ESBL-producing E. coli strain (tebipenem MIC, 0.03 mg/liter). Each panel represents the data from an individual fiber. The data represent the total bacterial population (open red triangles), a resistant subpopulation (open blue circles), and the pharmacokinetic profile of tebipenem (open black squares). The outputs from the mathematical model are shown using the same colors. The Bayesian posterior estimates for each fiber are shown. The fAUC0-24/MIC · 1/tau index values associated with the q24h, q12h, q8h, and q6h schedules are 17.3, 34.58, 51.87, and 69.15, respectively. Logarithmic killing was observed with at fAUC0-24/MIC · 1/tau values of 34.58 to 51.87, and suppression of resistance was observed at a value of 69.15. Panel A shows the control. In panels B to E, the same total amount of SPR859 has been administered in different schedules.

    Article Snippet: The genotypes of the challenge strains are shown in . table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Species Strain identifier Genotype Modal (range) tebipenem MIC (mg/liter) E. coli NCTC 13462 CTX-M2 0.016 (0.016) E. coli ATCC 35218 TEM-1 ESBL 0.016 (0.008–0.016) E. coli ATCC 25922 Wild type 0.016 (0.008–0.016) E. coli SPT 719 (JMI 742654) SHV-12, TEM-1 0.03 (0.03–0.25) E. coli SPT 720 (JMI 850505) mcr-1 , CMY-2, OXA-1, TEM1 0.5 (0.25–0.5) E. coli SPT 731 (JMI 845741) CTX-M-15, OXA-1/30, TEM-1 ST131 a O25b clade 0.03 (0.015–0.03) K. pneumoniae NCTC 13465 ESBL and CTX-M25 0.03 (0.015–0.03) K. pneumoniae ATCC 27736 Wild type 0.03 (0.03–0.06) K. pneumoniae SPT 725 (JMI 776273) SHV-12 0.125 (0.06–0.25) K. pneumoniae SPT 722 (JMI 934954) CTX-M-15, OXA-1, OXA-9, SHV-28, TEM-1, OmpK35 disrupted, OmpK36 altered 0.25 (0.12–0.5) K. pneumoniae SPT 723 (JMI 632346) CTX-M-15, OXA-1, SHV-12 0.125 (0.12) Open in a separate window a ST131, sequence type 131.

    Techniques: Infection